Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions
Appearance
Content deleted Content added
Ozzie10aaaa (talk | contribs) m Cleaned up using AutoEd |
Entranced98 (talk | contribs) Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound" |
||
Line 1: | Line 1: | ||
{{Short description|Monoclonal antibody}} |
|||
{{DISPLAYTITLE:Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan}} |
{{DISPLAYTITLE:Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan}} |
||
{{Drugbox |
{{Drugbox |
Revision as of 12:20, 13 May 2023
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | α-fetoprotein |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6470H9971N1712O2007S4290Y |
Molar mass | 145 kg/mol |
|
Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.
References